TwitterLinkedin

Contact Us

  • News & Events
    • News
    • Webinars
    • Events
  • Resource Library
    • Thought Leadership
    • Fact Flyers
    • Case Studies
    • White Papers
    • Webinars
    • Infographics
    • Video & Animation
  • Careers
    • Working at PharmaLex
    • Your Application Process
    • Current Opportunities
  • Training
Top Bar
Search
PharmaLex Logo
MENUMENU
  • PharmaLex Logo
  • PharmaLex Logo
  • About UsAbout Us
    • About Us
    • Management Team
    • Our Milestones
    • Corporate Social Responsibility
    • What Our Clients Say About Us
  • Our Services
    • Discovery / Non-clinical
          • Go to Discovery / Non-clinical section >>

          • Strategy and Consulting

            • Development Strategy and Gap Analysis
            • Integrated Product Development
            • Market Access
            • Non-clinical Development Concept
              and Study Design
            • Scientific Advice
            • Scientific Due Diligence
            • Statistical Services
            • Toxicology Services
    • Clinical Development
          • Go to Clinical Development section >>

          • Strategy and Consulting

            • Clinical Program Development
            • Orphan Drug Designation
            • Pediatric Investigation Plan (PIP)
            • Scientific Advice
            • Statistical Services
          • Regulatory Affairs

            • Clinical Trial Applications
            • Global Procedure Management
            • Health Authority / Agency Interaction
            • Regulatory Operations
          • Pharmacovigilance

            • Clinical Trial Safety Support
            • Pharmacovigilance Consulting
          • Quality

            • GxP Services
            • IMP Management
            • Interim / Contract QA
            • Quality Management Systems
            • Tech Transfer / Scale-up
            • Vendor Management and Oversight
    • Authorization / Approval
          • Go to Authorization / Approval section >>

          • Strategy and Consulting

            • Market Access
          • Regulatory Affairs

            • CMC Services
            • Global Procedure Management
            • Health Authority / Agency Interaction
            • Marketing and Labeling Activities
            • Regulatory Operations
            • Scientific, Regulatory and Technical Writing
            • Statistical Services
          • Pharmacovigilance

            • EU QPPV / National QPPV
            • Pharmacovigilance Consulting
          • Quality

            • Commercialization Readiness
            • Commissioning, Qualification, and Validation (CQV)
            • GxP Services
            • Interim / Contract QA
            • PAI Readiness
    • Post-approval / Maintenance
          • Go to Post-approval / Maintenance section >>

          • Strategy and Consulting

            • Environmental Risk Assessment
            • Market Access
          • Regulatory Affairs

            • CMC Services
            • Global End-to-End Outsourcing
            • Global Procedure Management
            • Health Authority / Agency Interaction
            • Marketing and Labeling Activities
            • Mergers and Acquisitions (M&A) Transfers
            • Regulatory Operations
            • Toxicology Services
          • Pharmacovigilance

            • Audit and CAPA Management
            • EU QPPV / National QPPV
            • ICSR Management
            • Literature Screening
            • Pharmacovigilance Systems
            • Safety Writing (PSUR, RMP)
            • Signal Management
          • Quality

            • Commissioning, Qualification, and Validation (CQV)
            • Good Distribution Practice (GDP) Compliance
            • GxP Services
            • Interim / Contract QA
            • Quality Management Systems
            • Vendor Audit
            • Vendor Management and Oversight
          • Medical Affairs

            • Healthcare Compliance and Medical Approval
            • Medical Information
    • Program Management
          • Go to Program Management section >>

          • Program Management

            • Global End-to-End Outsourcing
            • Global Procedure Management
            • Integrated Product Development
            • Mergers and Acquisitions (M&A) Transfers
    • Featured Expertise
          • Industry Expertise

            • Biopharmaceuticals
            • Consulting
            • Consumer Healthcare
            • Generics
            • Herbal Medicines
            • Medicinal Products
            • MedTech Services
            • Pharmaceutical
            • Veterinary Drugs
          • Service Expertise

            • ATMP / Cell and Gene Therapy
            • Brexit
            • COVID-19 Support
            • Drug Re-purposing / Value-added Medicines
            • GxP Services
            • Market Access
            • Pharmacovigilance Consulting
            • Statistical Services
            • SMARTPHLEX - technology-enabled services
  • Global ReachGlobal Reach
  • Contact usContact us
  • News & Events
    • News
    • Webinars
    • Events
  • Resource Library
    • Thought Leadership
    • Fact Flyers
    • Case Studies
    • White Papers
    • Webinars
    • Infographics
    • Video & Animation
  • Careers
    • Working at PharmaLex
    • Your Application Process
    • Career Opportunities
  • Training
Home > News & Events > Ireland > Cloud Computing in Pharma

Cloud Computing in Pharma

If you work in the pharma industry you are undoubtedly hearing discussions about the importance of the “cloud” but what exactly does this mean? Do you know how much of your organisation’s pharmaceutical data is “in the cloud” and how this data has made its way to the cloud? Hopefully by the time you have completed reading this article you will understand that “cirrus” and “cumulus”are not the only types of “cloud” that exist.

 

What exactly is cloud technology and how does it relate to the pharma industry?

Cloud computing is the on-demand availability of computer system resources, particularly in relation to data storage, without direct active management by the user. Data storage in the cloud means that company data is stored in data centres that can be located anywhere in the world and transmit the data to and from a location that you can personally access i.e. company IT systems, your own personal internet or mobile phone and other such devices.

 

Clouds can be limited to a single organisation and these are called “private” clouds. Cloud storage can also be available to multiple organisations (public cloud) or a combination of both (hybrid cloud). A hybrid cloud model operates in such a manner that data runs on a private cloud or data centre and bursts into a public cloud when the demand for computing capacity spikes. The advantage of this type of model is that an organisation only pays for the extra resources on as needed basis, however, consideration must be given to the security and compliance risks associated with cloud bursting.

 

When a pharmaceutical organisation engages in the use of cloud service providers this becomes an outsourced activity. The level of service that is outsourced by your organisation determines the type of IT model that has been employed. The different models that exist are as follows:

 

  • On premises
  • Infrastructure as a service (IAAS)
  • Platform as a service (PAAS)
  • Software as a service (SAAS)

 

The platforms of the cloud services providers can be shared amongst multiple different industrial sectors, ranging from the retail and motor industries to the pharmaceutical industry. It should not be assumed that cloud service providers are knowledgeable on pharmaceutical GxP requirements and it is up to the pharmaceutical industry to ensure that GxP requirements are being met. This can be achieved by conducting an audit of the cloud service provider and incorporating compliance requirements into Service Level Agreements, Quality Technical Agreements and through training. A description of the qualification requirements and ongoing management of IT service providers should also be present in the pharmaceutical Quality Management System. You own your data regardless of where it resides and it is imperative that you understand the controls that are in place to protect it.

 

Data integrity is a popular topic with both EU and US regulators. The FDA issued a Q&A Guidance Document for industry in December 2018 in relation to “Data Integrity and Compliance with Drug CGMP”. This was issued in direct response to increasing numbers of violations involving data integrity issues during CGMP inspections. This document contains some key questions that must be asked in order to ensure adequate oversight and control of the integrity of data that is generated. The questions identified are:

 

  • Are controls in place to ensure that data is complete?
  • Are activities documented at the time of performance?
  • Are activities attributable to a specific individual?
  • Can only authorised individuals make changes to records?
  • Is there a record of changes to data?
  • Are records reviewed for accuracy, completeness, and compliance with established
  • standards?
  • Are data maintained securely from data creation through disposition after the record’s

retention period

 

The full document can be viewed be clicking on the following link: http://academy.gmp-compliance.org/guidemgr/files/UCM495891.PDF

 

 

PharmaLex can support your organisation in many ways. If you would like support with a compliant transition of your organisation’s data to the cloud then contact the PharmaLex team. The types of services that PharmaLex can offer include qualification of cloud service providers, data integrity assessment reviews and development of data integrity programmes. Why not connect with PharmaLex today +353 1 846 4742 or  contactirl@pharmalex.com and discuss your individual needs with a member of the PharmaLex team.

Related posts
ERA merger
PharmaLex broadens biopharma expertise
5th March 2021
Supporting M&A in the pharmaceutical / biopharmaceutical industry
11th February 2021
Post-Brexit 2021 Health and Life Science Sector Impact
10th February 2021
Annex 1
EU GMP Annex 1
25th January 2021
mepharma partnership pharmalex
New Partnership Announcement for MEPHARMA and PharmaLex
21st January 2021
SMARTRISK
SMARTRISK – risk assessment excipient tool
12th January 2021
Search
Upcoming Webinars

March 18th, 2021

Critical Considerations for Mergers & Acquisitions

3 PM

March 23rd, 2021

US NDA versus EU MAA eCTDs – Exploiting the Synergies and Mastering the Differences

3 PM

March 24th, 2021

Post-Brexit 2021 Health and Life Science Sector Impact

3 PM CET

Upcoming Events

March 15 - 19th, 2021

DIA Europe 2021

March 22 - 25th, 2021

BIO Europe Spring 2021

Visit us at booth Virtual

June 14 - 17th, 2021

BIO International Convention 2021

June 27 - July 1st, 2021

DIA Annual Meeting 2021

September 22 - 24th, 2021

TOPRA Symposium 2021

Categories
  • All News
  • Webinars
  • Events
Archive
USEFUL LINKS
  • Home
  • Contact us
  • Imprint
  • Data Protection
  • Terms and Conditions
RECENT TWEETS
Tweets by @PharmaLexGLOBAL
COVID-19 NEWSLETTER SIGN UP

SIGN UP NOW

WHAT OUR CLIENTS SAY
  • Hard working and there when you need them

    Europe based large biotech
    Regulatory Manager
PharmaLex
©2021 PharmaLex GmbH. All rights reserved.

ISO9001:2015 LogoEnergie Audit Logo

#AskTheExpert #TogetherBEYONDCOVID19





    Select your state:

    .
    You can unsubscribe at any time at data.protection@pharmalex.com

    If you do not wish to receive any communication from us, you can unsubscribe at any time at. Click here to view our Privacy Policy.

    #TogetherBEYONDCOVID19

    We closely monitor developments and updates surrounding the current outbreak of Coronavirus Disease 2019 (COVID-19) from official sources including the World Health Organisation and are following the guidance and direction of the governments and the local authorities. We are taking this situation very seriously and our number one priority is the safety and business continuity for our customers and colleagues. As ever, we will do everything we can to ensure that services are delivered within the required time and the trusted quality PharmaLex is known for

      Please DO NOT send us event/conference information.
      We will not respond and these will be deleted immediately.





      Select your state:

      .
      You can unsubscribe at any time at
      data.protection@pharmalex.com

      If you do not wish to receive any communication from us, you can unsubscribe at any time at. Click here to view our Privacy Policy.

      Privacy Policy

      This can be specific information about signing up to the newsletter.

      Pellentesque lobortis, tellus at ultrices ullamcorper, lectus tellus consectetur lectus, id consequat leo quam quis eros. Mauris pellentesque tortor a augue pellentesque ultricies. Phasellus sit amet suscipit orci, vel dapibus ligula. Maecenas at pellentesque lectus, sit amet tristique felis. Integer fringilla risus ac neque mollis, at imperdiet lacus sodales. In vehicula orci sed vulputate interdum. Nunc sagittis non nunc eget sollicitudin.

      Maecenas a mattis erat. Phasellus cursus erat non nisl pulvinar ultricies. Aenean id fringilla libero. Orci varius natoque penatibus et magnis dis parturient montes, nascetur ridiculus mus. Morbi in ultrices elit. Suspendisse egestas hendrerit est. Integer pellentesque nisl ut justo tempus, nec suscipit dolor luctus. Cras vestibulum elementum tincidunt.

      In compliance with the Spanish Law 15/1999, of Protection of Personal Data and in accordance with regulations approved by the Spanish RD 994/1999 inform you that your data will be part of a file located in Friedrichsdorf (Germany), whose ownership belongs to Pharmalex Spain S.L.U. The purpose of these data is the insertion in a potential job selection process. Inform the user that at any time may exercise their right of access, rectification, and deletion of data through email curriculum@pharmalex.com or to this postal address Pharmalex Spain. Coso 103, 50001 Zaragoza, Spain.